WO2001070813A3 - REGULATION OF HUMAN GluR5-LIKE RECEPTOR - Google Patents

REGULATION OF HUMAN GluR5-LIKE RECEPTOR Download PDF

Info

Publication number
WO2001070813A3
WO2001070813A3 PCT/EP2001/003335 EP0103335W WO0170813A3 WO 2001070813 A3 WO2001070813 A3 WO 2001070813A3 EP 0103335 W EP0103335 W EP 0103335W WO 0170813 A3 WO0170813 A3 WO 0170813A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
regulation
glur5
reagents
disease
Prior art date
Application number
PCT/EP2001/003335
Other languages
French (fr)
Other versions
WO2001070813A2 (en
Inventor
Shyam Ramakrishnan
Original Assignee
Bayer Ag
Shyam Ramakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Shyam Ramakrishnan filed Critical Bayer Ag
Priority to AU2001252232A priority Critical patent/AU2001252232A1/en
Priority to EP01925504A priority patent/EP1290025A2/en
Publication of WO2001070813A2 publication Critical patent/WO2001070813A2/en
Publication of WO2001070813A3 publication Critical patent/WO2001070813A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reagents and methods for regulating the high affinity binding of GluR5-like receptor (GR5LR) to kainate are provided. Such reagents and methods can be used inter alia, to treat or prevent urinary incontinence, epilepsy, schizophrenia and other mood disorders, neurodegenerative diseases such as Huntington's disease and Alzheimer's disease, ischemia, and pain.
PCT/EP2001/003335 2000-03-24 2001-03-23 REGULATION OF HUMAN GluR5-LIKE RECEPTOR WO2001070813A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001252232A AU2001252232A1 (en) 2000-03-24 2001-03-23 Regulation of human glur5-like receptor
EP01925504A EP1290025A2 (en) 2000-03-24 2001-03-23 REGULATION OF HUMAN GluR5-LIKE RECEPTOR

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19175900P 2000-03-24 2000-03-24
US60/191,759 2000-03-24

Publications (2)

Publication Number Publication Date
WO2001070813A2 WO2001070813A2 (en) 2001-09-27
WO2001070813A3 true WO2001070813A3 (en) 2002-01-10

Family

ID=22706824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003335 WO2001070813A2 (en) 2000-03-24 2001-03-23 REGULATION OF HUMAN GluR5-LIKE RECEPTOR

Country Status (3)

Country Link
EP (1) EP1290025A2 (en)
AU (1) AU2001252232A1 (en)
WO (1) WO2001070813A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0529994A1 (en) * 1991-08-26 1993-03-03 Allelix Biopharmaceuticals Inc. Human KA-1 receptor, a kainate high affinity receptor of the EAA1 (Excitatory Amino Acid) family
US5547855A (en) * 1992-12-11 1996-08-20 Allelix Biopharmaceuticals Inc. Kainate-binding human CNS glutamate receptors EAA3C and EAA3D, DNA encoding them, and expression of the DNA in transformed cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0529994A1 (en) * 1991-08-26 1993-03-03 Allelix Biopharmaceuticals Inc. Human KA-1 receptor, a kainate high affinity receptor of the EAA1 (Excitatory Amino Acid) family
US5547855A (en) * 1992-12-11 1996-08-20 Allelix Biopharmaceuticals Inc. Kainate-binding human CNS glutamate receptors EAA3C and EAA3D, DNA encoding them, and expression of the DNA in transformed cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BETTLER ET AL.,: "Cloning of a new glutamate receptor subunit, GluR5: expression in the nervous system during development", NEURON, vol. 5, 1990, pages 583 - 595, XP001036529 *
DATABASE EMBL [online] 16 March 1999 (1999-03-16), XP002181555, Database accession no. AI435076 *
DATABASE EMBL [online] 4 December 1997 (1997-12-04), XP002181554, Database accession no. AA678689 *
DATABASE EMBL [online] 4 May 1995 (1995-05-04), XP002181553, Database accession no. R32841 *
HERB ANNE ET AL: "Q/R site editing in kainate receptor GluR5 and GluR6 pre-mRNAs requires distant intronic sequences.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 5, 1996, 1996, pages 1875 - 1880, XP002181552, ISSN: 0027-8424 *
SOMMER B ET AL: "A GLUTAMATE RECEPTOR CHANNEL WITH HIGH AFFINITY FOR DOMOATE AND KAINATE", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 11, no. 4, 1992, pages 1651 - 1656, XP001030827, ISSN: 0261-4189 *
SOMMER ET AL: "RNA editing in brain controls a determinant of ion flow in glutamate-gated channels", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 67, 4 October 1991 (1991-10-04), pages 11 - 19, XP002108292, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2001070813A2 (en) 2001-09-27
AU2001252232A1 (en) 2001-10-03
EP1290025A2 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
WO2001072831A3 (en) Immunoregulator
PL323871A1 (en) Compounds active at a new site on calcium passages controlled by a receptor, useful in treating neurological illnesses
BRPI0316438B8 (en) erythropoietin use in heart disease
WO2003007888A3 (en) Fat accumulation-modulating compounds
AU2002306848A1 (en) Methods of treating alzheimer's disease with piperidin derivates
JO2359B1 (en) Benzodiazepine derivatives as gaba a receptor modulators
BG106509A (en) Preparative form
SG157231A1 (en) Substituted p-diaminobenzene derivatives
AU2003296341A8 (en) System and method for treating Parkinson's Disease and other movement disorders
WO2001098279A3 (en) Bis-arylsulfones
WO2000059489A3 (en) Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
WO1999059617A3 (en) Immunoregulator
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
IL152688A0 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
WO2001070813A3 (en) REGULATION OF HUMAN GluR5-LIKE RECEPTOR
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2002006313A3 (en) Regulation of human glutamate receptor delta-1 subunit
WO2003037260A3 (en) Methods and compositions for treating parkinson's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001925504

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10221936

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001925504

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001925504

Country of ref document: EP